ciprofloxacin has been researched along with warfarin in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (14.89) | 18.7374 |
| 1990's | 11 (23.40) | 18.2507 |
| 2000's | 13 (27.66) | 29.6817 |
| 2010's | 14 (29.79) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Caron, G; Ermondi, G | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Avdeef, A; Tam, KY | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Hu, W; Lv, F; Shi, W; Xing, D; Yang, L; Yang, S; Yang, Y; Zhao, Z | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Bianco, TM; Bussey, HI; Farnett, LE; Linn, WD; Roush, MK; Wong, YW | 1 |
| Dugoni-Kramer, BM | 1 |
| Grasela, TH; Green, L; Jolson, HM; Tanner, LA | 1 |
| Joe, RH; Johnson, KC; Self, TH | 1 |
| Finkbeiner, S; Renzi, R | 1 |
| Garewal, HS; Jones, WN; Kelley, CL; Keuey, CL; Rindone, JP | 1 |
| Emory, C; Graves, L; Linville, D | 1 |
| Kamada, AK | 1 |
| Hunt, V; Mott, FE; Murphy, S | 1 |
| Elie, C; Forterre, P; Possot, O; Sibold, L; Sioud, M | 1 |
| Bia, FJ; Divo, AA; Patton, CL; Sartorelli, AC | 1 |
| Aldridge, KE; Janney, A; Sanders, CV | 1 |
| Klastersky, J; Van der Auwera, P | 1 |
| Joly, P; Van der Auwera, P | 1 |
| Glauser, MP; Malinverni, R; Perronne, CM | 1 |
| Howard, BM; Pinney, RJ; Smith, JT | 2 |
| Heller, AH; Israel, DS; Kamada, AK; Klein, C; Lettieri, JT; Pluhar, RE; Polk, RE; Rock, W; Sintek, CD; Stotka, J; Swaim, WR; Toscano, JP | 1 |
| Bodensteiner, DM; Ellis, RJ; Mayo, MS | 1 |
| Blance, SJ; Heddle, JG; Hollfelder, F; Maxwell, A; Miller, DA; Walsh, CT; Wentzell, LM; Zamble, DB | 1 |
| Miesbach, W | 1 |
| Berner, B; Campanella, C; Hou, SY; Hughes, NC; Washington, C | 1 |
| Gagne, JJ; Maio, V; Rabinowitz, C | 1 |
| Carroll, DG; Carroll, DN | 1 |
| Aiello, D; Barnes, MH; Bowlin, TL; Butler, MM; Di, M; Li, B; Moir, DT; Pai, R; Peet, NP; Tashjian, TF | 1 |
| Balmat, RP; Saum, LM | 1 |
| Bharate, JB; Bharate, SB; Joshi, P; Khan, IA; Kumar, A; Sharma, S; Singh, S; Vishwakarma, RA; Wani, A | 1 |
| Abd El-Hamid, SM; El-Attar, MS; Elshafie, HS; Sadeek, SA | 1 |
| Brancaglion, GA; Carvalho, DT; Coutinho, HDM; de Lemos Caldas, FR; de Paulo, DC; Farias, PAM; Figueredo, FG; Fonteles, MMF; Freitas, TS; Lima, MA; Martin, ALAR; Menezes, IRA; Pereira, RLS; Ribeiro-Filho, J; Rocha, JE; Sampaio, NFL | 1 |
2 review(s) available for ciprofloxacin and warfarin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Interactions between warfarin and three commonly prescribed fluoroquinolones.
Topics: Aza Compounds; Ciprofloxacin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluoroquinolones; Humans; International Normalized Ratio; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Warfarin | 2008 |
3 trial(s) available for ciprofloxacin and warfarin
| Article | Year |
|---|---|
Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation.
Topics: Adult; Aged; Ciprofloxacin; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Prospective Studies; Prothrombin Time; Time Factors; Warfarin | 1992 |
Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anticoagulants; Ciprofloxacin; Double-Blind Method; Drug Interactions; Factor VII; Female; Humans; Male; Middle Aged; Prothrombin; Prothrombin Time; Warfarin | 1996 |
Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Infective Agents; Anticoagulants; Ciprofloxacin; Cross-Over Studies; Delayed-Action Preparations; Drug Interactions; Half-Life; Humans; Male; Middle Aged; Partial Thromboplastin Time; Prothrombin Time; Stereoisomerism; Tablets; Warfarin | 2007 |
42 other study(ies) available for ciprofloxacin and warfarin
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
Topics: Amidohydrolases; Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Oligopeptides; Structure-Activity Relationship | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Ciprofloxacin-warfarin interaction.
Topics: Aged; Ciprofloxacin; Drug Interactions; Humans; Male; Prothrombin Time; Warfarin; Wound Infection | 1991 |
Adverse reaction reporting of interaction between warfarin and fluoroquinolones.
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Drug Interactions; Female; Humans; Male; Middle Aged; Norfloxacin; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Warfarin | 1991 |
Drug interaction.
Topics: Ciprofloxacin; Drug Interactions; Humans; Male; Middle Aged; Prothrombin Time; Warfarin | 1991 |
Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect.
Topics: Ciprofloxacin; Drug Interactions; Female; Humans; Middle Aged; Partial Thromboplastin Time; Prothrombin Time; Safety; Warfarin | 1991 |
Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin.
Topics: Aged; Ciprofloxacin; Humans; Male; Middle Aged; Prothrombin Time; Warfarin | 1991 |
Ciprofloxacin and warfarin interaction.
Topics: Aged; Ciprofloxacin; Drug Interactions; Female; Gastrointestinal Hemorrhage; Humans; Stomach Ulcer; Warfarin | 1991 |
Possible interaction between ciprofloxacin and warfarin.
Topics: Aged; Ciprofloxacin; Drug Interactions; Humans; Male; Prothrombin Time; Pulmonary Embolism; Thrombophlebitis; Warfarin | 1990 |
Ciprofloxacin and warfarin.
Topics: Aged; Ciprofloxacin; Drug Interactions; Humans; Male; Prothrombin Time; Warfarin | 1989 |
Coumarin and quinolone action in archaebacteria: evidence for the presence of a DNA gyrase-like enzyme.
Topics: Aminocoumarins; Anti-Bacterial Agents; Archaea; Autoradiography; Bacteria; Ciprofloxacin; Coumarins; DNA Replication; DNA Topoisomerases, Type II; Drug Interactions; Electrophoresis, Agar Gel; Euryarchaeota; Halobacterium; Novobiocin; Plasmids | 1988 |
Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro.
Topics: Aminocoumarins; Animals; Anti-Infective Agents; Chloroquine; Ciprofloxacin; Coumarins; Drug Interactions; Drug Resistance; Enoxacin; Fluoroquinolones; Nalidixic Acid; Norfloxacin; Novobiocin; Ofloxacin; Oxolinic Acid; Pefloxacin; Plasmodium falciparum; Tetracycline; Topoisomerase II Inhibitors | 1988 |
Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations.
Topics: Aminocoumarins; Anti-Bacterial Agents; Bacteriophage Typing; Ciprofloxacin; Coumarins; Glycopeptides; Methicillin; Penicillin Resistance; Quinolines; Staphylococcus aureus; Teicoplanin | 1985 |
In vitro activity of coumermycin alone or in combination against Staphylococcus aureus and Staphylococcus epidermidis.
Topics: Aminocoumarins; Anti-Bacterial Agents; Ciprofloxacin; Coumarins; Drug Combinations; Microbial Sensitivity Tests; Quinolines; Rifabutin; Rifampin; Rifamycins; Staphylococcus aureus; Staphylococcus epidermidis | 1986 |
Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus.
Topics: Aminocoumarins; Anti-Bacterial Agents; Cell Wall; Ciprofloxacin; Coumarins; DNA-Directed RNA Polymerases; Drug Interactions; Glycopeptides; Humans; Rifabutin; Rifampin; Rifamycins; Staphylococcus aureus; Teicoplanin; Topoisomerase II Inhibitors; Vancomycin | 1987 |
Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.
Topics: Aminocoumarins; Animals; Ciprofloxacin; Cloxacillin; Coumarins; Drug Evaluation, Preclinical; Drug Therapy, Combination; Endocarditis, Bacterial; Gentamicins; Humans; Microbial Sensitivity Tests; Rats; Staphylococcal Infections; Staphylococcus aureus | 1987 |
Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
Topics: Aminocoumarins; Anti-Infective Agents; Ciprofloxacin; Coumarins; DNA Topoisomerases, Type II; Escherichia coli; Genes, Bacterial; Microbial Sensitivity Tests; Mutation; Nalidixic Acid; Norfloxacin; Novobiocin; Ofloxacin; Rifampin | 1994 |
Studies on mutational cross-resistance between ciprofloxacin, novobiocin and coumermycin in Escherichia coli and Staphylococcus warneri.
Topics: Aminocoumarins; Ciprofloxacin; Coumarins; Drug Resistance, Microbial; Escherichia coli; Mutation; Novobiocin; Phenotype; Staphylococcus | 1993 |
Ciprofloxacin-warfarin coagulopathy: a case series.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anticoagulants; Blood Coagulation Disorders; Ciprofloxacin; Drug Interactions; Female; Humans; Hypoprothrombinemias; Male; Middle Aged; Plasma; Prothrombin Time; Vitamin K; Warfarin | 2000 |
The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition.
Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; Bacterial Toxins; Bacteriocins; Calcium; Ciprofloxacin; Coumarins; Cytotoxins; DNA Gyrase; DNA Replication; DNA Topoisomerases, Type II; DNA-Directed DNA Polymerase; DNA, Superhelical; Escherichia coli; Kinetics; Models, Molecular; Mutation; Nucleic Acid Synthesis Inhibitors; Peptides; Protein Conformation; Quinolones; Substrate Specificity; Topoisomerase II Inhibitors; Yeasts | 2001 |
Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin.
Topics: Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Blood Coagulation Factors; Ciprofloxacin; Factor VIIa; Factor XIII; Factor XIII Deficiency; Female; Hemorrhage; Humans; Immunologic Factors; Middle Aged; Recombinant Proteins; Rituximab; Thrombosis; Time Factors; Warfarin | 2005 |
Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Aminophylline; Anti-Inflammatory Agents, Non-Steroidal; Barbiturates; Child; Child, Preschool; Ciprofloxacin; Drug Interactions; Drug Utilization; Female; Fluvoxamine; Humans; Italy; Male; Middle Aged; Outpatients; Theophylline; Warfarin | 2008 |
Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation, and antibacterial activities.
Topics: Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Coumarins; DNA, Bacterial; DNA, Single-Stranded; DnaB Helicases; Drug Resistance, Bacterial; Enzyme Assays; Fluorescence Resonance Energy Transfer; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcus aureus; Structure-Activity Relationship | 2012 |
Ceftriaxone Potentiates Warfarin Activity Greater Than Other Antibiotics in the Treatment of Urinary Tract Infections.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Cephalosporins; Ciprofloxacin; Drug Synergism; Drug Therapy, Combination; Humans; International Normalized Ratio; Penicillins; Retrospective Studies; Urinary Tract Infections; Warfarin | 2016 |
Discovery of 4-acetyl-3-(4-fluorophenyl)-1-(p-tolyl)-5-methylpyrrole as a dual inhibitor of human P-glycoprotein and Staphylococcus aureus Nor A efflux pump.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; Bacterial Proteins; Binding Sites; Biological Transport; Caco-2 Cells; Ciprofloxacin; Coumarins; Dogs; Ethidium; Humans; Madin Darby Canine Kidney Cells; Mice, Inbred BALB C; Models, Molecular; Multidrug Resistance-Associated Proteins; Pyrroles; Rifampin; Staphylococcus aureus | 2015 |
Spectroscopic Analyses and Antimicrobial Activity of Novel Ciprofloxacin and 7-Hydroxy-4-methylcoumarin, the Plant-Based Natural Benzopyrone Derivative.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Coordination Complexes; Coumarins; Humans; Ions; Ligands; Microbial Sensitivity Tests; Oxygen; Spectrophotometry, Infrared | 2022 |
In vitro and in silico evidences about the inhibition of MepA efflux pump by coumarin derivatives.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Coumarins; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Staphylococcus aureus | 2023 |